Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report.

× No keyword cloud information.

32 in total

1. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group.

Authors: M Gómez-Rubio; J C Porres; I Castillo; J A Quiroga; A Moreno; V Carreño
Journal: J Hepatol Date: 1990 Impact factor: 25.083

2. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.

Authors: Yasuji Arase; Kenji Ikeda; Akihito Tsubota; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Masahiro Kobayashi; Norio Akuta; Takashi Someya; Tetsuya Hosaka; Hitomi Sezaki; Mariko Kobayashi; Hiromitsu Kumada
Journal: Intervirology Date: 2004 Impact factor: 1.763

Review 3. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Authors: Masao Omata; Haruhiko Yoshida; Yasushi Shiratori
Journal: Clin Gastroenterol Hepatol Date: 2005-10 Impact factor: 11.382

4. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP.

Authors: Shiro Murashima; Masatoshi Tanaka; Makoto Haramaki; Shigeru Yutani; Yutaka Nakashima; Kazunori Harada; Tatsuya Ide; Ryukichi Kumashiro; Michio Sata
Journal: Dig Dis Sci Date: 2006-04 Impact factor: 3.199

5. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Authors: Thomas Berg; Michael von Wagner; Samer Nasser; Christoph Sarrazin; Tobias Heintges; Tilman Gerlach; Peter Buggisch; Tobias Goeser; Jens Rasenack; Gerd R Pape; Wolfgang E Schmidt; Birgit Kallinowski; Hartwig Klinker; Ulrich Spengler; Peter Martus; Ulrich Alshuth; Stefan Zeuzem
Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682

6. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

Authors: M Buti; M Medina; M A Casado; J B Wong; L Fosbrook; R Esteban
Journal: Aliment Pharmacol Ther Date: 2003-03-01 Impact factor: 8.171

7. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.

Authors: R San Miguel; J Mar; J M Cabasés; F Guillén-Grima; M Buti
Journal: Aliment Pharmacol Ther Date: 2003-03-15 Impact factor: 8.171

8. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up.

Authors: M Yousuf; Y Nakano; E Tanaka; T Sodeyama; K Kiyosawa
Journal: Scand J Gastroenterol Date: 1992-09 Impact factor: 2.423

9. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors: S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal: Lancet Date: 1995-10-21 Impact factor: 79.321

Review 10. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Authors: J Shepherd; J Jones; D Hartwell; P Davidson; A Price; N Waugh
Journal: Health Technol Assess Date: 2007-03 Impact factor: 4.014

2 in total

Review 1. Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

Authors: Gianni Testino; Paolo Borro
Journal: World J Hepatol Date: 2013-10-27

2. Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study.

Authors: Yumiko Nagao; Takumi Kawaguchi; Tatsuya Ide; Michio Sata
Journal: Virol J Date: 2012-11-22 Impact factor: 4.099

2 in total